Evidence map›Paper›PMID 39391702›Full record

ArticleEuropean clinical respiratory journal2024

Factors behind favorable long-term lung cancer survival in Norway compared to Denmark: a retrospective cohort study.

Anja Gouliaev, Janna Berg, Azza A Khalil, Susanne O Dalton, Torben R Rasmussen, Niels L Christensen

Abstract read
In one paragraph

Article in European clinical respiratory journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anja GouliaevDepartment of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark.ORCID https://orcid.org/0000-0002-6161-5936
Janna BergDepartment of Pulmonology, Vestfold Hospital Trust, Tønsberg, Norway.
Azza A KhalilDepartment of Oncology, Aarhus University Hospital, Aarhus, Denmark.
Susanne O DaltonCancer Survivorship, Danish Cancer Society Institute, Copenhagen, Denmark.
Torben R RasmussenDepartment of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark.
Niels L ChristensenDepartment of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Long-term survival of patients with non-small cell lung cancer (NSCLC) is considerably higher in Norway compared to Denmark, even though diagnostic work-up, treatment, and follow-up are comparable. We aim to explore factors behind favorable long-term survival for lung cancer patients in Norway compared to Denmark. Method: A retrospective cohort study of patients with NSCLC diagnosed between 2014 and 2016. From the Danish Lung Cancer Registry, 1000 patients were randomly selected, and 974 patients were included. From the Norwegian Vestfold Hospital Trust, 220 patients were randomly selected, and 218 were included. Data from medical records were obtained for all patients. The Danish and Norwegian cohorts were compared using the Pearson chi squared test and multivariate logistic regression analysis. Results: The two cohorts were comparable in terms of age, sex, and smoking history. However, the Danish patients had a higher number of pack-years (43.5 vs 34.5 Conclusions: We found a higher proportion of Norwegian patients diagnosed at potential curable stage and fewer heavy smokers compared to Danish patients. This could contribute to the superior long-term survival found in Norwegian NSCLC patients.

Indexed as

EpidemiologyLung cancerScandinavian and Nordic countriesSmokingSurvivalTreatment

Identifiers

PMID39391702
PMCPMC11465383

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.